AbCellera https://validator.w3.org/feed/docs/rss2.html Careers Home Team Partners No Access AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 Pipeline Discovery of diverse GPCR-targeted antibodies using integrated technologies Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release Redirecting T cells to tumor targets with functionally diverse CD3-binding antibodies Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies A rational approach for selecting CD3-binding antibodies for T-cell engager development Antibody candidates ready for IND-enabling studies Discovery of diverse GPCR-targeted antibodies Designing T-cell engagers to widen the therapeutic window Functional and specific T-cell engagers for a peptide-MHC tumor target Diverse CD28-binding antibodies for costimulatory T-cell engager development Development of PSMA x CD3 T-cell engagers using an integrated, functional approach Contact Target-dependent considerations for the design of bispecific T-cell engagers Publications AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 MAbs Targeting intracellular tumor antigens to fight cancer: discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC AbCellera to Present at Upcoming Investor Conferences in September AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies Press Kit AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 AbCellera Reports Q1 2024 Business Results AbCellera presents data on T-cell engagers against four tumor targets at AACR 2024 T-Cell Engager Platform AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 News & Events AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 T-cell Engagers AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 AbCellera Reports Q2 2024 Business Results AbCellera Reports Full Year 2023 Business Results AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions AbCellera Announces Resignation of Board Member AbCellera to Present at Upcoming Investor Conferences in March Science Translational Medicine ACS Omega Cell Reports Stem Cell Reports Science